Trial Profile
Cohort study evaluating the efficacy of denosumab to protect against aromatase inhibitor-induced bone loss in Japanese breast cancer patients.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 17 Nov 2016
Price :
$35
*
At a glance
- Drugs Denosumab (Primary)
- Indications Osteoporosis
- Focus Therapeutic Use
- Acronyms CYBORG003
- 14 Nov 2016 Status changed from recruiting to discontinued.
- 27 Aug 2014 New trial record